百奥泰：BAT5906上市许可申请获得受理

Core Viewpoint - The company Baiotai (688177) has received the acceptance notice from the National Medical Products Administration for its investigational drug BAT5906, which is aimed at treating neovascular (wet) age-related macular degeneration (nAMD) [1] Group 1 - The drug BAT5906 is an injectable monoclonal antibody [1] - The application for BAT5906's market approval has been officially accepted [1] - The targeted indication for BAT5906 is neovascular (wet) age-related macular degeneration (nAMD) [1]